| 李峥,尹茂山,王寅,尹华静,吴爽,戴学栋,王庆利,孙涛,于冰.口服胰高血糖素样肽-1受体激动剂研究进展及非临床评价的考虑[J].中国药事,2023,(7):825-833 |
| 口服胰高血糖素样肽-1受体激动剂研究进展及非临床评价的考虑 |
| Research Progress of Oral Glucagon-Like Peptide-1 Receptor Agonists and Consideration of Non-clinical Evaluation |
| 投稿时间：2022-08-06 |
| DOI：10.16153/j.1002-7777.2023.07.012 |
| 中文关键词: 胰高血糖素样肽-1 胰高血糖素样肽-l受体激动剂 2型糖尿病 口服 改剂型新药 安全性 非临床评价 |
| 英文关键词: glucagon-like peptide-1 glucagon-like peptide-1 receptor agonist Type 2 diabetes mellitus take orally modifi ed dosage form of new drugs security non-clinical evaluation |
| 基金项目: |
|
| 摘要点击次数: 1559 |
| 全文下载次数: 660 |
| 中文摘要: |
| 胰高血糖素样肽-1（Glucagon-like Peptide-1，GLP-1）是一种由肠道L细胞分泌的肠促胰素 （Incretin），根据人体血糖水平调控胰岛素和胰高血糖素分泌，维持血糖稳定。胰高血糖素样肽-l受体激动剂（GLP-1 Receptor Agonists，GLP-1RA）是近年来开发的新型降糖药，通过模拟天然GLP-1而激活GLP-1受体，达到控制血糖的目的，同时GLP-1RA还具有控制体质量和改善非酒精性脂肪肝等多重临床获益，正逐步成为治疗糖尿病的第一大处方药物。目前已上市的GLP-1RA主要为注射用药，而与注射给药相比，口服制剂给药方便、治疗痛苦小，患者依从性更好。口服GLP-1RA药物已成为新的糖尿病治疗药物的重要研发方向之一。本文梳理了目前在研GLP-1RA口服小分子和肽类降糖药的研发现状，分析该靶点药物研究应用进展，并从非临床有效性和安全性方面提供评价策略，以期为同类药物的研发和应用提供参考。 |
| 英文摘要: |
| Glucagon-like Peptide-1 (GLP-1) is a kind of incretin secreted by intestinal L cells, which regulates the secretion of insulin and glucagon according to the body's blood sugar level and maintains blood sugar stability. GLP-1 receptor agonists (GLP-1RA) is a new hypoglycemic drug developed in recent years, which activates GLP1 receptors by simulating natural GLP-1 to achieve the purpose of controlling blood sugar, while GLP-1RA also has multiple clinical benefi ts such as weight control and improvement of non-alcoholic fatty liver, and is gradually becoming the fi rst prescription drug for the treatment of diabetes. GLP-1RA that has been marketed is mainly injectable drugs, and compared with injection administration, oral preparations are convenient to administer, less painful to treat, and better patient compliance. Oral GLP-1RA has become one of the important research and development directions of new diabetes treatment drugs. In this paper, the current research and development status of GLP-1RA oral small molecule and peptide hypoglycemic drugs under research is summarized, the research and application progress of this target drug is analyzed, and evaluation strategies are provided from the aspects of nonclinical effi cacy and safety, in order to provide references for the development and application of similar drugs. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|